Lars began by emphasizing the urgency of advancing biotechnology safely. I reassured him that this is possible, highlighting two key factors: aggressive private sector investment, federally funded basic research, and science-based regulation.
Research and breakthroughs at the intersection of biology and medicine — from gene editing and synthetic biology to clinical trials, diagnostics, and the science driving next-generation therapies.
